WeDosify

News

Closed Loop Medicine has launched its first product in the US, a digital tool for personalising the dose of GLP-1 weight-loss therapies.

News

Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.